HIF1A and breast cancer: Whilst the potential clinical utility of HIF-1α and CAIX in ER + breast cancer has been discussed by several authors [7–12], the relationships between the in vivo tumour pathophysiology and the expression of hypoxia-regulated proteins are underexplored for this cancer type.